In a clinical trial aimed at evaluating the safety, pharmacology, and metabolic effects of PPARδ agonists in patients with mild-to-moderate AD, the participants were treated with T3D-959 for 14 days. This evidence concerns the gene PPARD and Alzheimer disease.